1.Austin, MA, Hokanson, JE, Edwards, KL. Hypertriglyceridemia as a cardiovascular risk factor. American Journal of Cardiology 1998; 81: 7b–12b.
2.Sarwar, N, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 2007; 115: 450–458.
3.Do, R, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nature Genetics 2013; 45: 1345–1352.
4.Souza, SJ, et al. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review. Revista da Associação Médica Brasileira 2013; 59: 186–198.
5.Young, J, et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antiviral Therapy 2005; 10: 585–591.
6.Manfredi, R and Chiodo, F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. Journal of Infection 2001; 42: 181–188.
7.Friis-Moller, N, et al. Class of antiretroviral drugs and the risk of myocardial infarction. The New England Journal of Medicine 2007; 356: 1723–1735.
9.Bernardino de la Serna, J, et al. Hypertension, HIV infection, and highly active antiretroviral therapy. Enfermedades Infecciosas y Microbiologia Clinica 2010; 28: 32–37.
10.Riddler, SA, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289: 2978–2982.
11.Dolan, SE, et al. Increased cardiovascular disease risk indices in HIV-infected women. Journal of Acquired Immune Deficiency Syndromes 2005; 39: 44–54.
12.Currier, J, et al. Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. Journal of Acquired Immune Deficiency Syndromes 2008; 48: 35–43.
13.World Health Organization. The Global Eradication of Smallpox: Final Report of the Global Commission for the Certification of Smallpox Eradication. Geneva: World Health Organization, 1980. (http://whqlibdoc.who.int/publications/a41438.pdf). Accessed 28 October 2014.
15.Triant, VA, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. Journal of Clinical Endocrinology & Metabolism 2007; 92: 2506–2512.
16.Schuster, DP, Gaillard, T, Osei, K. The cardiometabolic syndrome in persons of the African diaspora: challenges and opportunities. Journal of the Cardiometabolic Syndrome 2007; 2: 260–266.
17.Goedecke, JH, et al. Ethnic differences in serum lipoproteins and their determinants in South African women. Metabolism 2010; 59: 1341–1350.
18.Lozano, R, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 2012; 380: 2095–2128.
19.Li, JZ, et al. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. Journal of Infectious Diseases 2013; 207: 893–897.
20.Dillon, DG, et al. Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. International Journal of Epidemiology 2013; 42: 1754–1771.
21.Ware, LJ, et al. Evaluation of waist-to-height ratio to predict 5 year cardiometabolic risk in sub-Saharan African adults. Nutrition, Metabolism, and Cardiovascular Diseases 2014; 24: 900–907.
24.American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 (Suppl. 1): S62–S69.
25.Ackermann, RT, et al. Identifying adults at high risk for diabetes and cardiovascular disease using hemoglobin A1c National Health and Nutrition Examination Survey 2005–2006. American Journal of Preventive Medicine 2011; 40: 11–17.
27.Zocchetti, C, Consonni, D, Bertazzi, PA. Estimation of prevalence rate ratios from cross-sectional data. International Journal of Epidemiology 1995; 24: 1064–1067.
28.Zou, G. A modified Poisson regression approach to prospective studies with binary data. American Journal of Epidemiology 2004; 159: 702–706.
29.DerSimonian, R and Laird, N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7: 177–188.
30.Higgins, JP and Thompson, SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002; 21: 1539–1558.
31.Clark, SJ, et al. Cardiometabolic disease risk and HIV status in rural South Africa: establishing a baseline. BMC Public Health 2015; 15: 135.
32.Hill, A, Sawyer, W, Gazzard, B. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clinical Trials 2009; 10: 1–12.
33.Friis-Moller, N, et al. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179–1193.
34.Wester, CW, et al. Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges. HIV Therapy 2009; 3: 501–526.
35.den Boer, MA, et al. Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. Arteriosclerosis Thrombosis and Vascular Biology 2006; 26: 124–129.
36.Zhou, H, et al. HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. American Journal of Physiology. Gastrointestinal and Liver Physiology 2006; 291: G1071–G1080.
37.Maagaard, A and Kvale, D. Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity. Scandinavian Journal of Infectious Diseases 2009; 41: 808–817.
38.Divi, RL, et al. Morphological and molecular course of mitochondrial pathology in cultured human cells exposed long-term to zidovudine. Environmental and Molecular Mutagenesis 2007; 48: 179–189.
39.van Leth, F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Medicine 2004; 1: e19.
40.Tungsiripat, M, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 2010; 24: 1781–1784.
41.Liang, JS, et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Natural Medicines 2001; 7: 1327–1331.
42.Asiki, G, et al. Prevalence of dyslipidaemia and associated risk factors in a rural population in south-western Uganda: a community based survey. PLoS ONE 2015; 10: e0126166.
43.Mbunkah, HA, et al. Prevalence of metabolic syndrome in human immunodeficiency virus – infected patients from the south-west region of Cameroon, using the adult treatment panel III criteria. Diabetology and Metabolic Syndrome 2014; 6: 92.
44.Sumner, AE, et al. Low HDL-cholesterol with normal triglyceride levels is the most common lipid pattern in West Africans and African Americans with metabolic syndrome: implications for cardiovascular disease prevention. CVD Prevention and Control 2010; 5: 75–80.
45.Julius, H, et al. The burden of metabolic diseases amongst HIV positive patients on HAART attending The Johannesburg Hospital. Current HIV Research 2011; 9: 247–252.
46.Tesfaye, DY, et al. Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia. Diabetes and Metabolic Syndrome 2014; 8: 102–107.
47.Quercia, R, et al. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clinical Drug Investigation 2015; 35: 211–219.